Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.230 -0.230 (-3.56%)

Official Closing Price Updated: 7:00 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,098,036
Open	6.560
Bid (Size)	5.910 (1,800)
Ask (Size)	6.440 (600)
Prev. Close	6.460
Today's Range	5.970 - 6.600
52wk Range	4.360 - 14.06
Shares Outstanding	52,700,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

September 03, 2026

From Emergent BioSolutions

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

September 01, 2026

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	-50.2%	-50.2%
1 Month	-17.7%	-17.7%
3 Month	-26.2%	-26.2%
6 Month	-26.2%	-26.2%
1 Year	-20.4%	-20.4%

More News

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

September 01, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

August 31, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions (NYSE:EBS) Beats Q2 Estimates, but Stock Drops on NARCAN Impairment and Restructuring Costs ↗

August 05, 2026

Via Chartmill

Emergent BioSolutions (NYSE:EBS) Surges After Q1 Earnings Beat and Raised Profit Outlook ↗

April 30, 2026

Via Chartmill

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

August 31, 2026

From Emergent BioSolutions

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

August 25, 2026

From Pomerantz LLP

Via GlobeNewswire

Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 19, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 18, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law

August 17, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)

August 12, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Emergent Biosolutions Q2 Earnings Call Highlights ↗

August 08, 2026

Via MarketBeat

Wondering what's happening in today's after-hours session? ↗

August 05, 2026

Via Chartmill

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

August 05, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

August 05, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026

July 22, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government

June 29, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

June 04, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

May 28, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions to Participate in Upcoming Investor Conferences

May 20, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

May 18, 2026

From Emergent BioSolutions

Via GlobeNewswire

Emergent (EBS) Q1 2026 Earnings Transcript ↗

May 01, 2026

Via The Motley Fool

Emergent BioSolutions Reports First Quarter 2026 Financial Results

April 30, 2026

From Emergent BioSolutions

Via GlobeNewswire

Frequently Asked Questions

Is Emergent BioSolutions Inc. Common Stock publicly traded?

Yes, Emergent BioSolutions Inc. Common Stock is publicly traded.

What exchange does Emergent BioSolutions Inc. Common Stock trade on?

Emergent BioSolutions Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Emergent BioSolutions Inc. Common Stock?

The ticker symbol for Emergent BioSolutions Inc. Common Stock is EBS on the New York Stock Exchange

What is the current price of Emergent BioSolutions Inc. Common Stock?

The current price of Emergent BioSolutions Inc. Common Stock is 6.230

When was Emergent BioSolutions Inc. Common Stock last traded?

The last trade of Emergent BioSolutions Inc. Common Stock was at 09/03/26 07:00 PM ET

What is the market capitalization of Emergent BioSolutions Inc. Common Stock?

The market capitalization of Emergent BioSolutions Inc. Common Stock is 328.32M

How many shares of Emergent BioSolutions Inc. Common Stock are outstanding?

Emergent BioSolutions Inc. Common Stock has 328M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.